<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940627-2-00077</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> The provisions of the Act have been implemented through regulations issued by the Department of Commerce and adopted by the Department of Health and Human Services <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> .  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=1 --> 2 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> The Department of Commerce regulations are at 37 Code of Federal Regulations (CFR) Part 401 and supersede applicable portions of 45 CFR Parts 6 and 8.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FOOTNOTE>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The Act serves the public not only by encouraging the development of useful commercial products such as drugs and clinical diagnostic materials, but also by providing economic benefits, and enhancing U.S. competitiveness in the global market place.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Since its passage, the Bayh-Dole Act has been effective in promoting the transfer of technology from Grantees to industry as evidenced by the aggressive pursuit of patenting and licensing and the proliferation of university/industry collaborations. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 3 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  In addition, the development of many new and important drugs and devices have been facilitated by increased industrial support for academic research <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 4 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  and the explosion in the licensing of university owned inventions. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 5 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Furthermore, statistics indicate that the Act has provided significant economic benefits which are projected as increasing between 25 to 30 percent per year. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 6 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=1 --> 3 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> Approximately one in every four university patents issued in the late 1980s was for a biomedical or health related invention. In the early 1970's, the ratio was one in eight. Source: Science and Engineering Indicators, 1993, National Science Foundation.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FOOTNOTE>  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=1 --> 4 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> While still representing less than 10 percent of the total funding for academic research, it is estimated that nearly 2 percent of United States industry's expenditures for R&amp;D now goes to academic institutions, as compared with less than 1 percent in 1971. Source: Science and Engineering Indicators, 1993, National Science Foundation.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FOOTNOTE>  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=1 --> 5 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> Over 1000 licenses or options were executed in Fiscal Year 1992 by 260 academic institutions surveyed. The institutions also reported that they had over 5000 active licenses in place at the time of the survey. Source: Association of University Transfer Managers Licensing Survey FY 1991&hyph;1992, published October, 1993.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FOOTNOTE>  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=1 --> 6 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> In FY 1992 sales and employment attributable to the Act were estimated to be as follows: between $9 and $13 billion in sales and 50&hyph;100,000 jobs, with an annual increase of between 25 and 30 percent. Source: Dr. Ashley J. Stevens, Director, Office of Technology Transfer, Dana-Farber Cancer Institute, Association of University Technology Managers Winter Meeting, 1994.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FOOTNOTE>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Grantee Responsibilities  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In keeping with the objectives and policy of Bayh-Dole, it is incumbent upon Grantees to effectively and efficiently transfer technology to industry for commercial development. However, in doing so Grantees must also comply with the specific terms of the Act, its implementing regulations, and the terms and conditions of each NIH award and ensure that such compliance is reflected in their agreements with commercial entities.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> In carrying out that responsibility, at a minimum, Grantees need to concern themselves with issues involving maintenance of academic freedom for institutions and investigators, fair access to information, timeliness of notification and other requirements, rational licensing to commercial entities, and adherence to the specific requirements of the Act and NIH funding agreements.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            